Aptose Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Selling, General & Admin	13.38	11.15	15.59	14.51	19.46	Upgrade
Research & Development	11.34	15.1	36.77	28.09	45.99	Upgrade
Operating Expenses	24.72	26.26	52.36	42.6	65.45	Upgrade
Operating Income	-24.72	-26.26	-52.36	-42.6	-65.45	Upgrade
Interest Expense	-0.84	-0.21	-	-	-	Upgrade
Interest & Investment Income	0.11	0.36	1.15	0.79	0.09	Upgrade
Currency Exchange Gain (Loss)	-0.01	-0.01	-0	-0.01	-0	Upgrade
Other Non Operating Income (Expenses)	-	0.69	-	-	-	Upgrade
Pretax Income	-25.47	-25.43	-51.21	-41.82	-65.35	Upgrade
Net Income	-25.47	-25.43	-51.21	-41.82	-65.35	Upgrade
Net Income to Common	-25.47	-25.43	-51.21	-41.82	-65.35	Upgrade
Shares Outstanding (Basic)	2	1	0	0	0	Upgrade
Shares Outstanding (Diluted)	2	1	0	0	0	Upgrade
Shares Change (YoY)	250.13%	210.44%	9.81%	3.57%	8.86%	Upgrade
EPS (Basic)	-10.41	-36.38	-227.43	-203.98	-330.12	Upgrade
EPS (Diluted)	-10.41	-36.38	-227.43	-203.98	-330.12	Upgrade
Free Cash Flow	-21.99	-35.98	-44.62	-32.35	-43.52	Upgrade
Free Cash Flow Per Share	-8.98	-51.48	-198.17	-157.76	-219.81	Upgrade
EBITDA	-24.7	-26.23	-52.27	-42.48	-65.3	Upgrade
D&A For EBITDA	0.02	0.03	0.09	0.12	0.15	Upgrade
EBIT	-24.72	-26.26	-52.36	-42.6	-65.45	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.